ライフサイエンスコーパス: serotonin reuptake inhibitor

1 atory agents, corticosteroids, and selective serotonin reuptake inhibitors).

2 mpus following administration of a selective serotonin reuptake inhibitor.

3 ocking properties of fluoxetine, a selective serotonin reuptake inhibitor.

4 in conjunction with an open-label selective serotonin reuptake inhibitor.

5 itor, the other from paroxetine, a selective serotonin-reuptake inhibitor.

6 ars to lack drug interactions with selective serotonin reuptake inhibitors.

7 ting the antidepressant actions of selective serotonin reuptake inhibitors.

8 Depressive patients medicated with Selective Serotonin Reuptake Inhibitors.

9 tracyclic antidepressants and norepinephrine-serotonin reuptake inhibitors.

10 in patients that do not respond to selective serotonin reuptake inhibitors.

11 he absence of prenatal exposure to selective serotonin reuptake inhibitors.

12 ly active medications such as tricyclics and serotonin reuptake inhibitors.

13 tive to SERT inhibitors, including selective serotonin reuptake inhibitors.

14 itivity, and response to long-term selective serotonin reuptake inhibitors.

15 ared with TCAs and strong compared with weak serotonin reuptake inhibitors.

16 disorder, GAD, or use of benzodiazepines or serotonin reuptake inhibitors.

17 nt to the first line of treatment (selective serotonin reuptake inhibitors)(1).

18 splays competitive binding towards selective serotonin reuptake inhibitors(15,16).

19 benefit are often switched to non-selective serotonin reuptake inhibitor agents.

20 In contrast, the use of selective serotonin reuptake inhibitors (aHR for MOF, 1.43; 95% CI

21 Clinical trial data support selective serotonin reuptake inhibitors and amantadine to assist m

22 Regarding safety, serotonin reuptake inhibitors and bupropion may have low

23 Effective treatments for OCD include serotonin reuptake inhibitors and cognitive-behavioural

24 rapy) and pharmacotherapy, such as selective serotonin reuptake inhibitors and serotonin-norepinephri

25 inhibitors, patients taking higher doses of serotonin reuptake inhibitors and who had a longer durat

26 cological treatments, particularly selective serotonin-reuptake inhibitors and serotonin-noradrenalin

27 iazepines (-0.96, -1.56 to -0.36), selective serotonin-reuptake inhibitors and serotonin-norepinephri

28 lthy volunteers with citalopram (a selective serotonin reuptake inhibitor) and contrasted its effects

29 cts differential response to escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norep

30 benzodiazapines, and withdrawal of selective serotonin-reuptake inhibitor) and received cyproheptadin

31 erational effects of sertraline, a selective serotonin reuptake inhibitor, and venlafaxine, a seroton

32 cluding tricyclic antidepressants, selective serotonin reuptake inhibitors, and norepinephrine reupta

33 as atypical antipsychotic agents, selective serotonin reuptake inhibitors, and selective serotonin-n

34 -related issues: suicide risk with selective serotonin reuptake inhibitors, and the safety of antidep

35 and that the neurogenic effects of selective serotonin reuptake inhibitor antidepressants can success

36 Serotonin reuptake inhibitors appear efficacious, but th

37 Selective serotonin reuptake inhibitors are the most widely prescr

38 Current treatments, such as selective serotonin reuptake inhibitors, are not ideal because onl

39 Compared with selective serotonin reuptake inhibitors as a drug class, other cla

40 Standard guidelines recommend selective serotonin reuptake inhibitors as first-line antidepressa

41 ce continues to support the use of selective serotonin reuptake inhibitors as first-line pharmacologi

42 ASD associated with treatment with selective serotonin reuptake inhibitors by the mother during the y

43 year risk of MOF by 36% for use of selective serotonin reuptake inhibitors, by 63% for use of mood st

44 of hip fracture by 57% for use of selective serotonin reuptake inhibitors, by 98% for use of mood st

45 double-blind design to receive the selective serotonin reuptake inhibitor citalopram (20 mg) or place

46 We observed dissociable effects of the serotonin reuptake inhibitor citalopram and the dopamine

47 We therefore examined whether the selective serotonin reuptake inhibitor citalopram improves respons

48 The selective serotonin reuptake inhibitor citalopram reduced mortalit

49 A subset of animals received selective serotonin reuptake inhibitor citalopram starting 7 days

50 agonists (BI-11A7 and BI-2A7); the selective serotonin reuptake inhibitor citalopram was used as a po

51 ctivity of a subactive dose of the selective serotonin reuptake inhibitor citalopram.

52 hallenge with an acute dose of the selective serotonin reuptake inhibitor, citalopram, revealed a gen

53 in response to challenge with the selective serotonin reuptake inhibitor, citalopram.

54 sting that serotonin-receptor antagonists or serotonin reuptake inhibitors could represent therapeuti

55 benzodiazepine, and 293 were treated with a serotonin reuptake inhibitor during pregnancy.

56 c deletion or brief treatment with selective serotonin reuptake inhibitors during development, have a

57 Use of selective serotonin reuptake inhibitors during the second and/or t

58 of exposure to fluoxetine (FLX), a selective serotonin reuptake inhibitor, during adolescence on beha

59 e of antidepressants, specifically selective serotonin reuptake inhibitors, during the second and/or

60 get for antidepressants, including selective serotonin reuptake inhibitors (e.g. (S)-citalopram) and

61 without its deleterious effect on selective serotonin reuptake inhibitor efficacy.

62 8 weeks with either placebo or the selective serotonin reuptake inhibitor escitalopram.

63 with subsequent remission with the selective serotonin reuptake inhibitor escitalopram; this is consi

64 8 weeks after randomization to the selective serotonin reuptake inhibitors escitalopram and sertralin

65 ponded significantly better to the selective serotonin reuptake inhibitors escitalopram and sertralin

66 oma were randomized to either placebo or the serotonin reuptake inhibitor, escitalopram (ESC) 10-20 m

67 ether a 3-week administration of a selective serotonin reuptake inhibitor, expected to increase brain

68 o benefit from bupropion following selective serotonin reuptake inhibitor failures.

69 -hydroxytryptamine [5-HT]) and the selective serotonin reuptake inhibitor fluoxetine (FLX) have both

70 the antidepressant efficacy of the selective-serotonin reuptake inhibitor fluoxetine (FLX) in a chron

71 In contrast, the serotonin reuptake inhibitor fluoxetine (FLX) reduced im

72 mented behavioral responses to the selective serotonin reuptake inhibitor fluoxetine but not desipram

73 The serotonin reuptake inhibitor fluoxetine selectively supp

74 Treatment with the selective serotonin reuptake inhibitor fluoxetine suppressed BMP s

75 Postnatal treatment with the selective serotonin reuptake inhibitor fluoxetine, evokes anxiety

76 reversed by administration of the selective serotonin reuptake inhibitor fluoxetine.

77 ort and binding of cocaine and the selective serotonin reuptake inhibitors fluoxetine and escitalopra

78 ally exposed to acute doses of the selective serotonin reuptake inhibitor, fluoxetine (5 or 25 mg/L),

79 Administration of the selective serotonin reuptake inhibitor, fluoxetine, abrogated beha

80 ssical therapeutics, including the selective serotonin reuptake inhibitor, fluoxetine.

81 sterone blocked the ability of the selective serotonin reuptake inhibitor, fluvoxamine, to inhibit se

82 of adults with MDD treated with a selective serotonin reuptake inhibitor for their depressive sympto

83 gether with the demonstrated efficacy of the serotonin reuptake inhibitors for childhood-onset obsess

84 re nondopaminergic approaches (eg, selective serotonin reuptake inhibitors for psychiatric symptoms,

85 egan demonstrating the efficacy of selective serotonin reuptake inhibitors for these conditions in th

86 -current stimulation (tDCS) with a selective serotonin-reuptake inhibitor for the treatment of depres

87 -CCKR-2 tg mice with fluoxetine, a selective serotonin reuptake inhibitor, for a period of 4 wk signi

88 Fluoxetine, a selective serotonin reuptake inhibitor, has been found recently to

89 Fluoxetine, a selective serotonin reuptake inhibitor, has been reported to reduc

90 cortex are powerfully modulated by selective serotonin reuptake inhibitors, however, direct measureme

91 uld be relevant to some actions of selective serotonin reuptake inhibitors in humans.

92 er a 12-week treatment course with selective serotonin reuptake inhibitors in late-life depression.

93 Long-term efficacy and safety of selective serotonin reuptake inhibitors in these patients are unkn

94 The efficacy and adverse events of selective serotonin reuptake inhibitors in these patients are unkn

95 of children exposed prenatally to selective serotonin reuptake inhibitors in this population was low

96 We identified citalopram, a selective serotonin reuptake inhibitor, in a small molecule screen

97 iological effects of fluoxetine, a selective serotonin reuptake inhibitor, in filter and deposit feed

98 vo-administered drug citalopram, a selective serotonin reuptake inhibitor, in mouse brain tissue sect

99 Maternal treatment with a serotonin reuptake inhibitor is also associated with hyp

100 aroxetine (Paxil), the most potent selective serotonin reuptake inhibitor known.

101 Treatment with serotonin reuptake inhibitors may be most beneficial in

102 substances, such as increasingly prescribed serotonin reuptake inhibitors, may produce an independen

103 rols); unmedicated-MDD; and MDD treated with serotonin reuptake inhibitors (MDD*SSRI) or tricyclics (

104 treated, n = 12), MDD treated with selective serotonin reuptake inhibitors (MDD*SSRI, n = 6) or tricy

105 treatments-cognitive behavioral therapy and serotonin reuptake inhibitor medication-for managing bot

106 e-enhanced behavior therapy) and medication (serotonin reuptake inhibitors, N-acetylcysteine, or nalt

107 ession classified as responsive to selective serotonin reuptake inhibitors (odds ratio=1.55, 95% CI=1

108 s into the effects of OLZ, but not selective serotonin reuptake inhibitors, on core features of AN.

109 antidepressant medication therapy (selective serotonin reuptake inhibitor or serotonin and norepineph

110 0-week open-label treatment with a selective serotonin reuptake inhibitor or, in some cases, another

111 setron) either in combination with selective serotonin reuptake inhibitors or as monotherapy in the t

112 treatment of depression by use of selective serotonin reuptake inhibitors or psychological approache

113 in 5 systematic reviews) and with selective serotonin reuptake inhibitors or selective serotonin and

114 lly untreated maternal depression, selective serotonin reuptake inhibitors or serotonin and norepinep

115 wnregulated by the acute action of selective serotonin reuptake inhibitors or serotonin at the site o

116 preterm birth are high for women who used a serotonin reuptake inhibitor (OR, 1.55 [95% CI, 1.02-2.3

117 rval [CI] = 1.10-15.14) and use of selective serotonin reuptake inhibitors (OR = 2.66; 95% CI = 1.01-

118 cluding tricyclic antidepressants, selective serotonin reuptake inhibitors, or alpha-2-delta calcium

119 edicted response to antidepressants overall, serotonin reuptake inhibitors, or noradrenaline reuptake

120 2 by the clinically approved antidepressant, serotonin reuptake inhibitor paroxetine (PX), recapitula

121 Recently we identified the serotonin reuptake inhibitor paroxetine as an inhibitor

122 s applied to the synthesis of the commercial serotonin reuptake inhibitor (-)-paroxetine.

123 The selective serotonin reuptake inhibitor, paroxetine, was previously

124 Compared with patients who were not taking serotonin reuptake inhibitors, patients taking higher do

125 Although current antidepressants, such as serotonin-reuptake inhibitors, produce subtle changes th

126 muli, and possible off-target effects of the serotonin reuptake inhibitor Prozac.

127 reatment of Hoxb8 mutants with fluoxetine, a serotonin reuptake inhibitor, reduces excessive grooming

128 Fluoxetine is the only selective serotonin reuptake inhibitor registered for the treatmen

129 behavioral therapy with or without selective serotonin reuptake inhibitors remains a preferred initia

130 hether this model is responsive to selective serotonin reuptake inhibitors remains unspecified.

131 in women with MDD or anxiety, with selective serotonin reuptake inhibitors reported as the most commo

132 f classic antidepressants, such as selective serotonin reuptake inhibitors, require a month or longer

133 e itch triggered by serotonin or a selective serotonin reuptake inhibitor required both HTR7 and TRPA

134 nt exposure to fluoxetine (FLX), a selective serotonin reuptake inhibitor, results in changes to the

135 help clinicians decide when to use selective serotonin reuptake inhibitor/serotonin-norepinephrine re

136 case report suggested benefit from selective serotonin reuptake inhibitor/serotonin-norepinephrine re

137 as generally unclear if outpatient selective serotonin reuptake inhibitor/serotonin-norepinephrine re

138 excess morbidity in critically ill selective serotonin reuptake inhibitor/serotonin-norepinephrine re

139 Selective serotonin reuptake inhibitor/serotonin-norepinephrine re

140 dies of ICU patients with recorded selective serotonin reuptake inhibitor/serotonin-norepinephrine re

141 exposed and control groups; use of selective serotonin reuptake inhibitor/serotonin-norepinephrine re

142 nxiety disorders are treated using selective serotonin reuptake inhibitors-small molecules that compe

143 Participants were 73 serotonin reuptake inhibitor (SRI) nonresponders with ma

144 ne unmedicated (n = 12) and one treated with serotonin reuptake inhibitors (SRI; n = 13).

145 Notably, serotonin reuptake inhibitors (SRIs) are antidepressant

146 Serotonin reuptake inhibitors (SRIs) are efficacious tre

147 Serotonin reuptake inhibitors (SRIs) are the only medica

148 der (OCD) indicates that partial response to serotonin reuptake inhibitors (SRIs) is the norm and tha

149 Serotonin reuptake inhibitors (SRIs), the first-line pha

150 rder (OCD) exhibit an inadequate response to serotonin reuptake inhibitors (SRIs).

151 iety disorders, which are often treated with serotonin reuptake inhibitors (SRIs).

152 Chronic selective serotonin reuptake inhibitor (SSRI) administration to ro

153 ndicated that the combination of a selective serotonin reuptake inhibitor (SSRI) and a statin may hav

154 ollowing administration of several selective serotonin reuptake inhibitor (SSRI) antidepressant drugs

155 splays distinct sensitivity to the selective serotonin reuptake inhibitor (SSRI) antidepressant fluox

156 The association between selective serotonin reuptake inhibitor (SSRI) antidepressant use d

157 sant medication or specifically to selective serotonin reuptake inhibitor (SSRI) antidepressants, all

158 , either untreated or treated with selective serotonin reuptake inhibitor (SSRI) antidepressants, and

159 Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepressants, has

160 ian subjects were administered the selective serotonin reuptake inhibitor (SSRI) citalopram (10 mg) i

161 Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases

162 his study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram downregul

163 er a single 20-mg oral dose of the selective serotonin reuptake inhibitor (SSRI) citalopram or placeb

164 -HT neurons with a low dose of the selective serotonin reuptake inhibitor (SSRI) citalopram synergist

165 The selective serotonin reuptake inhibitor (SSRI) fluoxetine (FLX), th

166 e early anxiogenic response to the selective serotonin reuptake inhibitor (SSRI) fluoxetine and had i

167 s and advantages compared with the selective serotonin reuptake inhibitor (SSRI) fluoxetine.

168 aled that chronic treatment with a selective serotonin reuptake inhibitor (SSRI) impairs the acquisit

169 A subset of patients started on a selective serotonin reuptake inhibitor (SSRI) initially experience

170 cally supported psychotherapy with selective serotonin reuptake inhibitor (SSRI) pharmacotherapy as t

171 or to beginning treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline or cognit

172 (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy.

173 the relationship between prenatal selective serotonin reuptake inhibitor (SSRI) treatment and pregna

174 Although selective serotonin reuptake inhibitor (SSRI) treatment is known t

175 itive-behavioral therapy (CBT) and selective serotonin reuptake inhibitor (SSRI) treatment outcome in

176 obust therapeutic response to evidence-based serotonin reuptake inhibitor (SSRI) treatment.

177 (RR 1.48, 1.29-1.71), and maternal selective serotonin reuptake inhibitor (SSRI) use during pregnancy

178 ERT) were synthesized based on the selective serotonin reuptake inhibitor (SSRI), (S)-citalopram (1).

179 fects of duloxetine hydrochloride, selective serotonin reuptake inhibitor (SSRI), and covariates on t

180 Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), blocks GCS-induced

181 via direct amygdala infusions of a selective serotonin reuptake inhibitor (SSRI), citalopram.

182 In the presence of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), concentrations of 5

183 Chronic administration of a selective serotonin reuptake inhibitor (SSRI), fluoxetine, increas

184 re not rescued with the prototypic selective serotonin reuptake inhibitor (SSRI), fluoxetine.

185 ted the effects of escitalopram, a selective serotonin reuptake inhibitor (SSRI), on brain activation

186 es demonstrated that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), provided the most s

187 after ~8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI).

188 c, but not acute, treatment with a selective serotonin reuptake inhibitor (SSRI).

189 nt with citalopram, a prototypical selective serotonin reuptake inhibitor (SSRI).

190 after 8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI).

191 we show that when the effects of a selective serotonin reuptake inhibitor (SSRI, citalopram) are stud

192 Selective serotonin reuptake inhibitors (SSRI's) enhance neural pl

193 Selective serotonin reuptake inhibitors (SSRI) are aimed at increa

194 Selective serotonin reuptake inhibitors (SSRI) are known to increa

195 rated that acute administration of selective serotonin reuptake inhibitors (SSRI) can affect P-gp fun

196 at the selective 5-hydroxytryptamine (5-HT) (serotonin) reuptake inhibitor (SSRI) fluoxetine (Flx) is

197 e, antidepressant use and classes (selective serotonin reuptake inhibitors [SSRI], serotonin-norepine

198 sms explaining hormetic effects of selective serotonin reuptake inhibitors (SSRIs) and 4-nonylphenol

199 strongest evidence supports use of selective serotonin reuptake inhibitors (SSRIs) and cognitive-beha

200 ollowing two first-line treatments-selective serotonin reuptake inhibitors (SSRIs) and cognitive-beha

201 ors, both of which are reversed by selective serotonin reuptake inhibitors (SSRIs) and the tricyclic

202 Selective serotonin reuptake inhibitors (SSRIs) are a first-line t

203 Selective serotonin reuptake inhibitors (SSRIs) are antidepressant

204 Compared with placebo, selective serotonin reuptake inhibitors (SSRIs) are associated wit

205 Selective serotonin reuptake inhibitors (SSRIs) are commonly presc

206 Selective serotonin reuptake inhibitors (SSRIs) are commonly presc

207 Selective Serotonin Reuptake Inhibitors (SSRIs) are commonly used

208 Selective serotonin reuptake inhibitors (SSRIs) are first-line pha

209 Selective serotonin reuptake inhibitors (SSRIs) are frequently pre

210 Selective serotonin reuptake inhibitors (SSRIs) are often recommen

211 Selective serotonin reuptake inhibitors (SSRIs) are standard of ca

212 pressive disorder (MDD), for which selective serotonin reuptake inhibitors (SSRIs) are the first line

213 Selective serotonin reuptake inhibitors (SSRIs) are the most commo

214 Selective serotonin reuptake inhibitors (SSRIs) are the most presc

215 Selective serotonin reuptake inhibitors (SSRIs) are the most widel

216 Selective serotonin reuptake inhibitors (SSRIs) are the primary ph

217 Although selective serotonin reuptake inhibitors (SSRIs) are widely prescri

218 Selective serotonin reuptake inhibitors (SSRIs) are widely used an

219 Selective serotonin reuptake inhibitors (SSRIs) are widely used an

220 Selective serotonin reuptake inhibitors (SSRIs) are widely used an

221 Are selective serotonin reuptake inhibitors (SSRIs) associated with be

222 f amygdala serotonin reuptake with selective serotonin reuptake inhibitors (SSRIs) confirmed the caus

223 Selective serotonin reuptake inhibitors (SSRIs) constitute a first

224 Selective serotonin reuptake inhibitors (SSRIs) display a delayed

225 w-strength evidence was found that selective serotonin reuptake inhibitors (SSRIs) do not reduce cann

226 an association between the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy a

227 Use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy h

228 It is unknown whether exposure to selective serotonin reuptake inhibitors (SSRIs) during pregnancy i

229 Use of selective serotonin reuptake inhibitors (SSRIs) has been associate

230 otonin transporter, (Slc6a4/SERT), selective serotonin reuptake inhibitors (SSRIs) improve mood in ad

231 The safety and efficacy of selective serotonin reuptake inhibitors (SSRIs) in adolescents is

232 dulation of synaptic plasticity by selective serotonin reuptake inhibitors (SSRIs) in hippocampal bra

233 ted that the treatment response to selective serotonin reuptake inhibitors (SSRIs) in major depressiv

234 blockers potentiate the effects of selective serotonin reuptake inhibitors (SSRIs) in some treatment-

235 gated whether in utero exposure to selective serotonin reuptake inhibitors (SSRIs) increases the risk

236 sporter or postnatal blockade with selective serotonin reuptake inhibitors (SSRIs) leads to novelty-i

237 Selective serotonin reuptake inhibitors (SSRIs) may increase the r

238 g animals with MAO-A inhibitors or selective serotonin reuptake inhibitors (SSRIs) normalized anxiety

239 SM) advised against treatment with selective serotonin reuptake inhibitors (SSRIs) other than fluoxet

240 Selective serotonin reuptake inhibitors (SSRIs) represent a class

241 Compared with pill placebo, selective serotonin reuptake inhibitors (SSRIs) significantly redu

242 D, and clinical data indicate that selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine

243 Selective Serotonin Reuptake Inhibitors (SSRIs) such as fluoxetine

244 ion accounting for unsatisfactory effects of serotonin reuptake inhibitors (SSRIs) such as insufficie

245 m concomitant use of nsNSAIDs with selective serotonin reuptake inhibitors (SSRIs) was 1.6, whereas t

246 udies linking in utero exposure to selective serotonin reuptake inhibitors (SSRIs) with persistent pu

247 orepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and maternal depr

248 respond to initial treatment with selective serotonin reuptake inhibitors (SSRIs), and this is assoc

249 logic data indicate that among the selective serotonin reuptake inhibitors (SSRIs), citalopram and es

250 rinatal exposure to drugs, such as selective serotonin reuptake inhibitors (SSRIs), impacts cortical

251 Selective serotonin reuptake inhibitors (SSRIs), in addition to th

252 rtioxetine might be different from selective serotonin reuptake inhibitors (SSRIs), including larger

253 Most antidepressants, including selective serotonin reuptake inhibitors (SSRIs), initiate their dr

254 ge of therapeutic agents including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradre

255 he relative efficacy and safety of selective serotonin reuptake inhibitors (SSRIs), serotonin-norepin

256 promising candidates that are both selective serotonin reuptake inhibitors (SSRIs), sertraline and es

257 Selective serotonin reuptake inhibitors (SSRIs), such as citalopra

258 e brain pro-serotonergic effect of selective serotonin reuptake inhibitors (SSRIs), without the usual

259 itro and functionally responded to selective serotonin reuptake inhibitors (SSRIs).

260 ved in patients chronically taking selective serotonin reuptake inhibitors (SSRIs).

261 aviour following acute exposure to selective serotonin reuptake inhibitors (SSRIs).

262 i-inflammatory drugs (NSAIDs), and selective serotonin reuptake inhibitors (SSRIs).

263 the introduction and diffusion of selective serotonin reuptake inhibitors (SSRIs).

264 sive Disorder who are treated with Selective Serotonin Reuptake Inhibitors (SSRIs).

265 havioral and cellular responses to selective serotonin reuptake inhibitors (SSRIs).

266 partial response or no response to selective serotonin reuptake inhibitors (SSRIs).

267 eclampsia among women treated with selective serotonin reuptake inhibitors (SSRIs).

268 emical and behavioral responses to selective serotonin reuptake inhibitors (SSRIs).

269 nitive-behavioral therapy (CBT) or selective serotonin reuptake inhibitors (SSRIs).

270 HTR7 and clinical response to four selective serotonin reuptake inhibitors (SSRIs: citalopram, paroxe

271 that examined fixed doses of five selective serotonin reuptake inhibitors (SSRIs; citalopram, escita

272 ation and is commonly treated with selective serotonin reuptake inhibitors (SSRIs; e.g., Prozac).

273 Whether the use of selective serotonin-reuptake inhibitors (SSRIs) and other antidepr

274 eductase inhibitors (statins), and selective serotonin-reuptake inhibitors (SSRIs) and serotonin-nore

275 The use of selective serotonin-reuptake inhibitors (SSRIs) has been associate

276 nuates the therapeutic activity of selective serotonin-reuptake inhibitors (SSRIs), whereas their fun

277 Antidepressant use (selective serotonin reuptake inhibitors [SSRIs] or serotonin-norep

278 ine to comparators (venlafaxine or selective serotonin reuptake inhibitors [SSRIs], and individuals w

279 all, for 4 antidepressant classes (selective serotonin reuptake inhibitors [SSRIs], tricyclic and rel

280 d that n-3 PUFAs and escitalopram (selective serotonin reuptake inhibitors, SSRIs) treatment increase

281 ith subchronic administration of a selective serotonin reuptake inhibitor, suggesting the predictive

282 cluding tricyclic antidepressants, selective serotonin reuptake inhibitors, tegaserod, and histamine-

283 ch were themselves associated with selective serotonin reuptake inhibitor treatment outcomes in patie

284 oral changes were rescued by acute selective serotonin reuptake inhibitor treatment, supporting the h

285 sed to assess cataract surgery and selective serotonin reuptake inhibitor treatment.

286 Acute SSRI (selective serotonin reuptake inhibitor) treatment has been shown t

287 ute odds ratios for differences in selective serotonin reuptake inhibitor use between cases and contr

288 Selective serotonin reuptake inhibitor use of 1 or more years in p

289 Selective serotonin reuptake inhibitor use of 1 or more years was

290 Maternal serotonin reuptake inhibitor use was associated with hyp

291 ion was shortened by 3.6 days; with maternal serotonin reuptake inhibitor use, gestation was shortene

292 of depression, length of lifetime selective serotonin reuptake inhibitor use, or lifetime length of

293 York Heart Association class, and selective serotonin reuptake inhibitor use.

294 of 6024 residents, 1024 (17%) were selective serotonin reuptake inhibitor users compared to 788 (13%)

295 etics, antiparkinsonian drugs, and selective serotonin reuptake inhibitors, we sought to determine th

296 For SERT analysis, patients on selective serotonin reuptake inhibitor were excluded (n = 48 remai

297 s who were partial responders to a selective serotonin reuptake inhibitor were randomized to receive

298 Findings for prenatal exposure to selective serotonin reuptake inhibitors were similar.

299 This study compared a serotonin reuptake inhibitor with a noradrenergic/dopami

300 used to examine the effect of treatment with serotonin reuptake inhibitors, with or without antipsych